News
-
News
10 July 2018
Allyson Kaye to step down as Chair after 13 years
After 13 years as Chair of Ovarian Cancer Action, Allyson Kaye MBE has announced her decision to step down. We are delighted that Allyson will continue her close connection with the charity in her new role of President, acting as an advisor and ambassador. Our current Vice-Chair, Dr Wayne Phillips has been appointed in her stead and Allyson will work closely with Wayne and the board as they embark on an exciting new chapter for the charity.
-
News
28 June 2018
More women could be eligible for groundbreaking ovarian cancer drug
The Telegraph has reported today that the latest trials of the drug Olaparib (Lynparza) have produced results that could make it accessible for a significantly increased number of women with advanced stage ovarian cancer.
-
News
20 June 2018
Ovarian Cancer Action receives £150,000 at NEX Giving Day
Ovarian Cancer Action was honoured to have been nominated as one of the six chosen charities for the first NEX Giving Day, held in London on 7th June.
-
News
15 June 2018
Ovarian Cancer Action scientists discover mechanism that ‘deactivates’ ovarian cancer cells
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells, which could lead to better treatments for women with ovarian cancer.
-
News
10 June 2018
Ovarian Cancer Action launches Hereditary Cancer Risk Tool
This week sees the launch of Ovarian Cancer Action's Hereditary Cancer Risk Tool, which has been developed to help people identify their cancer risk. We believe everyone has the right to understand if their family history puts them at risk of ovarian and other cancers, as well as the risk-reducing options available.
-
News
01 June 2018
'Breakthrough' blood test could detect ovarian cancer in its earliest stages
In today’s news, a blood test has been hailed a ‘possible holy grail’ in the early detection of ovarian cancer. The...
-
News
01 June 2018
Ovarian cancer drug Niraparib approved for NHS use
The National Institute for Health and Care Excellence (NICE) have today announced that a new drug, Niraparib, has been recommended for use in the Cancer Drugs Fund as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer.
-
News
30 May 2018
What is patient data and how can it help cancer research?
This month marks a big change in health services as the NHS introduces a new national data opt-out service to give patients more control over how their personal information is used. We take a look at the new system and how data acts as a powerful tool in cancer research.
-
News
22 May 2018
Artificial intelligence to improve cancer diagnosis
Ovarian Cancer Action welcomes today’s announcement from the Prime Minister to use emerging technologies to transform cancer diagnosis in the UK, saving around 22,000 lives a year by 2033.
-
News
15 May 2018
Scientists identify cause of resistance to ovarian and breast cancer drug
Scientists at the Institute of Cancer Research have identified a genetic mutation that causes cancer cells to become resistant to PARP inhibitors, such as olaparib, which are used to treat ovarian and breast cancers.
-
News
08 May 2018
APPG publishes report on early diagnosis of ovarian cancer
The Ovarian Cancer All-Party-Parliamentary-Group (APPG) has today published a report “Diagnosing ovarian cancer sooner: what more can be done?” to mark World Ovarian Cancer Day.
-
News
04 May 2018
World Ovarian Cancer Day 2018: 7,400 roses
Tuesday 8th May is World Ovarian Cancer Day and we’re joining forces with ovarian cancer communities from around the globe to raise awareness of the disease and highlight the need to fund research.
-
News
16 February 2018
Study reveals new genetic mutation passed on by men that increases risk of ovarian cancer
A study published today in PLoS Genetics has uncovered a new genetic mutation that fathers can pass onto their daughters through the X chromosome.
-
News
07 February 2018
Promising new ovarian cancer treatment could soon be available on the NHS
The National Institute for Health and Care Excellence (NICE) has issued draft guidance on a promising new ovarian cancer drug, niraparib, advising that it is a suitable candidate for use in the Cancer Drugs Fund (CDF).
-
News
31 January 2018
New report ranks UK ovarian cancer survival 45th out of 59 countries
UK ovarian cancer survival rates rank 45th out of 59 countries across the globe, according to research published today in medical journal The Lancet.
-
News
19 January 2018
Ovarian Cancer Action partners with Pureology
Ovarian Cancer Action is delighted to announce a partnership with Pureology; a leading L’Oréal haircare brand
-
News
19 January 2018
New blood test could help detect eight different cancers
Widely reported in the news today is the story that scientists have taken a step towards developing a universal blood test for cancer.
-
News
18 January 2018
BRCA testing for women over 30 could save thousands of lives
A study at Queen Mary University London has revealed that screening all women over 30 for BRCA genetic mutations could prevent tens of thousands of cases of breast and ovarian cancer.
-
News
18 December 2017
Life-extending ovarian cancer drug licensed for use in the UK
There has been exciting news today, with the announcement that niraparib, a new drug for women with ovarian cancer, has been approved for use in the UK.
-
News
07 December 2017
Britain Against Cancer Conference
The annual Britain Against Cancer conference is a day that brings around 400 people together for the biggest day in the Parliamentary calendar focused on cancer. Yesterday our Head of Campaigns, Marie-Claire, headed to Westminster to talk all things ovarian cancer: